Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis As Chairman Of The Board

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

"We are enthusiastic to have the opportunity to work with Dr. Lewis in his new capacity as Chairman of the Board. Given the recent filing of an IND with the FDA to initiate a dose escalating Phase I/II clinical trial in lung cancer, we believe that having a Chairman with the industry experience of Dr. Lewis will strategically position Batu Biologics for entry into partnerships and collaborations with others in the field," Said Samuel Wagner, President and CEO of Batu Biologics.

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.